Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
SAN CARLOS, Calif., May 02, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in May:
- Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 2:50 p.m. ET
- UBS Global Healthcare Conference in New York, NY on Monday, May 21, 2018 at 2:30 p.m. ET
A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
